AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) (the ?Company?), today announced that, pursuant to a previously announced shareholder vote, the Company will change its name to...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will...
Please replace the release with the following corrected version due to multiple revisions. AVANT REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Conference Call...
AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today reported financial results for the second quarter and six-month period ended June 30, 2008. AVANT reported a net loss of...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its second quarter 2008 financial results before U.S. financial markets open on August 6, 2008. AVANT executives...
Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) today announced multi-year clinical research collaborations with the 3M to...
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.